ANX005 ( DrugBank: ANX005 )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
8	ハンチントン病	1
61	自己免疫性溶血性貧血	6

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000325-26-FR (EUCTR)	29/04/2021	19/02/2021	Phase 2 safety and tolerability study using ANX005 for ALS	Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Intravenous ANX005in Su ...	Amyotrophic Lateral Scelrosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Code: ANX005 INN or Proposed INN: ANX005 Other descriptive name: IMMUNOGLOBULIN G	Annexon Biosciences	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	25	Phase 2	United States;France;Canada

First Previous1Next Last

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04514367 (ClinicalTrials.gov)	August 17, 2020	27/7/2020	An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease	A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic ...	Huntington Disease	Drug: ANX005	Annexon, Inc.	NULL	Completed	18 Years	N/A	All	28	Phase 2	United States

First Previous1Next Last

61. 自己免疫性溶血性貧血

臨床試験数 : 146 / 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04691570 (ClinicalTrials.gov)	November 10, 2021	28/12/2020	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005in Participants With Warm Autoi ...	A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) a ...	Warm Autoimmune Hemolytic Anemia (wAIHA)	Drug: ANX005	Annexon, Inc.	NULL	Completed	18 Years	N/A	All	6	Phase 2	United States
2	EUCTR2020-003675-18-BG (EUCTR)	28/10/2021	29/07/2021	Study to Assess the Safety, Tolerability, Efficacy, PK, PD and POC of Intravenous ANX005in Patients ...	A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharm ...	Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: ...	Product Code: ANX005 INN or Proposed INN: ANX005 Other descriptive name: ANX005	Annexon, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	United States;France;Czechia;Spain;Austria;Australia;Bulgaria;Germany;Italy
3	EUCTR2020-005854-90-AT (EUCTR)	11/02/2021	05/01/2021	Investigation of the influence of ANX005on the body of patients with primary cold agglutinin disease ...	A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmaco ...	Primary Cold Agglutinin Disease (CAD);Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Code: ANX005 INN or Proposed INN: ANX005 Other descriptive name: Recombinant humanized IgG4 mo ...	Annexon, Inc.	NULL	Not Recruiting			Female: yes Male: yes	6	Phase 2	Austria
4	EUCTR2020-003675-18-AT (EUCTR)	05/02/2021	10/12/2020	Study to Assess the Safety, Tolerability, Efficacy, PK, PD and POC of Intravenous ANX005in Patients ...	A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharm ...	Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: ...	Product Code: ANX005 INN or Proposed INN: ANX005 Other descriptive name: ANX005	Annexon, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	France;United States;Czechia;Spain;Australia;Austria;Bulgaria;Germany;United Kingdom;Italy
5	EUCTR2020-003675-18-DE (EUCTR)	11/01/2021	28/09/2020	Study to Assess the Safety, Tolerability, Efficacy, PK, PD and POC of Intravenous ANX005in Patients ...	A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharm ...	Warm Autoimmune Hemolytic Anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: ...	Product Code: ANX005 INN or Proposed INN: ANX005 Other descriptive name: ANX005	Annexon, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	France;United States;Czechia;Spain;Austria;Australia;Bulgaria;Germany;Italy
6	EUCTR2020-003675-18-IT (EUCTR)	11/12/2020	02/08/2021	Study to Assess the Safety, Tolerability, Efficacy, PK, PD and POC of Intravenous ANX005in Patients ...	A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharm ...	warm autoimmune hemolytic anemia MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: ...	Product Name: ANX005 Product Code: [ANX005] Other descriptive name: Recombinant humanized monoclonal a ...	Annexon, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2	France;Hungary;Spain;Austria;Norway;Netherlands;Germany;United Kingdom;Italy

First Previous1Next Last

先頭へ